SCP
DFTX

Sender Company & Partners’s Definium Therapeutics DFTX Stock Holding History

Sender Company & Partners’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-25,906
Closed -$305K – 313
2025
Q3 		$305K Buy
+25,906
New +$242K 0.03% 333

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Sender Company & Partners's DFTX Position: Q4 2025 in Review

Sender Company & Partners sold out of Definium Therapeutics (DFTX) in Q4 2025, closing a stake of 25,906 shares — an estimated $305K sold.

Sender Company & Partners first reported a position in DFTX in Q3 2025 and held it in 1 quarter. The position peaked at $305K in Q3 2025. 208 funds tracked by Wall St. Rank hold DFTX as of Q4 2025.

  • Sender Company & Partners reported no remaining Definium Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Sender Company & Partners sold 25,906 Definium Therapeutics shares in Q4 2025, an estimated $305K.
  • Sender Company & Partners first reported a position in Definium Therapeutics in Q3 2025 and held it in 1 quarter.
  • Sender Company & Partners's Definium Therapeutics position peaked at $305K in Q3 2025.
  • 208 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2025.

Based on Sender Company & Partners's 13F filing for Q4 2025, filed 17 Feb 2026.